StreetInsider.com News Articles

Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Barclays

Wed, 19 Aug 2026 03:21:01 -0400

Barclays analyst Glen Santangelo raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $20.00) while maintaining a Equalweight rating.

Form 144 Amphastar Pharmaceutical Filed by: Petersen Floyd F.

Tue, 18 Aug 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945684.html

Form 144 Amphastar Pharmaceutical Filed by: Petersen Floyd F.

Tue, 18 Aug 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260818/26945684.html

Form 4 Amphastar Pharmaceutical For: Aug 11 Filed by: PRINS RICHARD K

Wed, 12 Aug 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26914621.html

Form 4 Amphastar Pharmaceutical For: Aug 11 Filed by: PRINS RICHARD K

Wed, 12 Aug 2026 18:15:00 -0400

si-local-file:///var/storage/secattach/20260812/26914621.html

Form 4 Amphastar Pharmaceutical For: Aug 07 Filed by: PETERS WILLIAM J

Tue, 11 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26906807.html

Form 4 Amphastar Pharmaceutical For: Aug 07 Filed by: PETERS WILLIAM J

Tue, 11 Aug 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260811/26906807.html

Form 144 Amphastar Pharmaceutical Filed by: PRINS RICHARD K

Tue, 11 Aug 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260811/26903968.html

Form 144 Amphastar Pharmaceutical Filed by: PRINS RICHARD K

Tue, 11 Aug 2026 11:53:00 -0400

si-local-file:///var/storage/secattach/20260811/26903968.html

Form 144 Amphastar Pharmaceutical Filed by: PETERS WILLIAM J

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891095.html

Form 144 Amphastar Pharmaceutical Filed by: PETERS WILLIAM J

Fri, 07 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260807/26891095.html

Amphastar Pharmaceuticals (AMPH) PT Raised to $20 at Wells Fargo

Fri, 07 Aug 2026 08:20:44 -0400

Wells Fargo analyst Benjamin Burnett raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $19.00) while maintaining a Equal Weight rating.

Amphastar Pharmaceuticals (AMPH) PT Lowered to $20 at Piper Sandler

Fri, 07 Aug 2026 07:48:23 -0400

Piper Sandler analyst David Amsellem lowered the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $20.00 (from $21.00) while maintaining a Neutral rating.

Amphastar Pharma (AMPH) Tops Q2 EPS by 28c

Fri, 07 Aug 2026 02:31:07 -0400

Amphastar Pharma (NASDAQ: AMPH) reported Q2 EPS of $0.91, $0.28 better than the analyst estimate of $0.63. Revenue for the quarter came in at $183.9 million versus the consensus estimate of $179.71 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

Form 10-Q Amphastar Pharmaceutical For: Jun 30

Thu, 06 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260806/26885148.html

Form 10-Q Amphastar Pharmaceutical For: Jun 30

Thu, 06 Aug 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260806/26885148.html

Form 8-K Amphastar Pharmaceutical For: Aug 06

Thu, 06 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26884774.html

Form 8-K Amphastar Pharmaceutical For: Aug 06

Thu, 06 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260806/26884774.html

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

RANCHO CUCAMONGA, Calif., Aug. 6, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, today

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Thu, 06 Aug 2026 16:05:00 -0400

Net revenues of $183.9 million for the three months ended June 30, 2026

GAAP net income of $30.3 million, or $0.67 per share, for the second quarter

Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter

Company to hold a conference call today at 2:00 p.m. Pacific Time